Global Custom Market Research Reports Provider Company

phone

Atrial Fibrillation - Pipeline Review, H2 2018

  • Published Date: 07 Aug 2018
  • Number of Pages: 92
  • Category: Pharmaceuticals
  • Country: Global
Atrial Fibrillation - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2018, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, light headedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular)
List of TablesNumber of Products under Development for Atrial Fibrillation, H2 2018 9Number of Products under Development by Companies, H2 2018 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide
List of TablesNumber of Products under Development for Atrial Fibrillation, H2 2018 9Number of Products under Development by Companies, H2 2018 The guide covers therapeutics under Development by Companies /Universities /Institutes,
List of TablesNumber of Products under Development for Atrial Fibrillation, H2 2018 9Number of Products under Development by Companies, H2 2018

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is
List of TablesNumber of Products under Development for Atrial Fibrillation, H2 2018 9Number of Products under Development by Companies, H2 2018 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Atrial Fibrillation - Overview
Atrial Fibrillation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Atrial Fibrillation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Atrial Fibrillation - Companies Involved in Therapeutics Development
Acesion Pharma Aps
AnaBios Corp
ARCA biopharma Inc
Boston Pharmaceuticals Inc
Correvio Pharma Corp
Daiichi Sankyo Co Ltd
Dong-A Socio Holdings Co Ltd
Gilead Sciences Inc
HUYA Bioscience International LLC
InCarda Therapeutics Inc
Merck & Co Inc
N-Gene Research Laboratories Inc
Nissan Chemical Industries Ltd
OMEICOS Therapeutics GmbH
The Geneva Biotech Center SA
Atrial Fibrillation - Drug Profiles
AFC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-30663 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGP-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-1728515 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bucindolol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budiodarone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flecainide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBCA-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBI-3000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heparin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-1832 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIP-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vernakalant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrial Fibrillation - Dormant Projects
Atrial Fibrillation - Discontinued Products
Atrial Fibrillation - Product Development Milestones
Featured News & Press Releases
Jul 17, 2018: OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation
Jun 11, 2018: Correvio Provides U.S. Regulatory Update for BRINAVESS
May 18, 2018: LIXIANA (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Hemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organization Conference 2018
May 17, 2018: Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess in China
Apr 27, 2018: Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics
Apr 17, 2018: Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess
Mar 12, 2018: Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation
Feb 08, 2018: Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation
Dec 12, 2017: Espero BioPharma Provides Update on Budiodarone
Nov 15, 2017: New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017
Nov 13, 2017: OMEICOS Announces Formation of Inaugural Clinical Advisory Board
Nov 08, 2017: Daiichi Sankyo Announces New Analyses of Once-Daily SAVAYSA (edoxaban) to be Presented at the 2017 American Heart Association Scientific Sessions
Nov 02, 2017: Cardiome Announces Expansion of Global Geographic Footprint for Brinavess
Oct 06, 2017: Daiichi Sankyo to Install Call Center Support System in Japan Utilizing Artificial Intelligence
Sep 14, 2017: G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Atrial Fibrillation, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H2 2018
Atrial Fibrillation - Pipeline by AnaBios Corp, H2 2018
Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H2 2018
Atrial Fibrillation - Pipeline by Boston Pharmaceuticals Inc, H2 2018
Atrial Fibrillation - Pipeline by Correvio Pharma Corp, H2 2018
Atrial Fibrillation - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018
Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H2 2018
Atrial Fibrillation - Pipeline by HUYA Bioscience International LLC, H2 2018
Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H2 2018
Atrial Fibrillation - Pipeline by Merck & Co Inc, H2 2018
Atrial Fibrillation - Pipeline by N-Gene Research Laboratories Inc, H2 2018
Atrial Fibrillation - Pipeline by Nissan Chemical Industries Ltd, H2 2018
Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H2 2018
Atrial Fibrillation - Pipeline by The Geneva Biotech Center SA, H2 2018
Atrial Fibrillation - Dormant Projects, H2 2018
Atrial Fibrillation - Dormant Projects, H2 2018 (Contd..1), H2 2018
Atrial Fibrillation - Dormant Projects, H2 2018 (Contd..2), H2 2018
Atrial Fibrillation - Discontinued Products, H2 2018
Atrial Fibrillation - Discontinued Products, H2 2018 (Contd..1), H2 2018

List Of Figures

List of Figures
Number of Products under Development for Atrial Fibrillation, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018 T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T

View Report

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018 Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4

View Report

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2018 Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports